Skip to main content
Equibles
GOSS logo

GOSS · Gossamer Bio, Inc.

Track GOSS — free

Use GOSS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about GOSS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.15 -0.02 (-9.45%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$75.38M
Shares
488.85M

Gossamer Bio, Inc. Earnings Call Transcripts

Every quarterly earnings call for Gossamer Bio, Inc. (GOSS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$42.50M '23 Q2 23-08-08 · $9.89M −$36.64M '25 Q1 25-05-15 ▲71.5% $16.95M −$46.66M '26 Q1 26-05-18 LATEST ▼19.6% $9.24M $16.90M '26 Q2 26-07-27
Earnings call
FY26 · Q2
2026-07-27
Gossamer Bio, Inc. Q2 FY2026 Earnings Call
Revenue
$9.24M
▼ 19.6% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-18
Gossamer Bio, Inc. Q1 FY2026 Earnings Call
Positive tone CT-FRI sub-study and reverse remodeling Procera Phase III results and clinical signal Confirmatory evidence from TORI Phase II
Revenue
$16.95M
▲ 71.5% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Gossamer Bio, Inc. Q1 FY2025 Earnings Call
Confident tone Seralutinib commercial opportunity PROSERA Phase III enrollment Competitive landscape (sotatercept, Tyvaso)
Revenue
$9.89M
Diluted EPS
$-0.16
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Gossamer Bio, Inc. Q2 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Gossamer Bio, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Gossamer Bio, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-0.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Gossamer Bio, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-0.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Gossamer Bio, Inc. Q1 FY2021 Earnings Call
Diluted EPS
$-0.78
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Gossamer Bio, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Gossamer Bio, Inc. Q3 FY2020 Earnings Call
Diluted EPS
$-0.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Gossamer Bio, Inc. Q1 FY2020 Earnings Call
Diluted EPS
$-0.87
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts CIK 1728117 CUSIP 38341P102 13F (30d) 169 filings 166 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)